Travere Therapeutics(TVTX) - 2024 Q2 - Quarterly Results
Travere Therapeutics(TVTX)2024-08-01 20:05Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2024 Financial Results ® Received 521 new patient start forms (PSFs) for FILSPARI (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product sales of FILSPARI totaled $27.1 million for the second quarter of 2024 representing 37% growth over the previous quarter Company well-posi ...